Panzara Michael A. 4
4 · IMMUNIC, INC. · Filed Apr 29, 2026
Research Summary
AI-generated summary of this filing
Immunic CMO Michael Panzara Receives 300,000-Share Option Award
What Happened
Michael A. Panzara, Chief Medical Officer of Immunic, Inc. (IMUX), was granted 300,000 derivative shares (an option award) on April 24, 2026. The Form 4 reports an acquisition price of $0.00 and a reported value of $0 for the transaction; the award is a time-vested equity grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-04-24; Form filed: 2026-04-29 (filed five days after the transaction; may be late relative to the typical two-business-day Form 4 deadline).
- Shares/units granted: 300,000 (reported as a derivative/security award). Reported acquisition price: $0.00.
- Shares owned after transaction: Not specified in the provided filing.
- Footnote: The options are time-vested — 50% vest on April 24, 2027; the remaining 50% vests in 24 equal monthly installments thereafter, subject to continued employment in good standing.
Context
This is a compensation-style option grant (not a purchase or sale). Time-based vesting means the award becomes usable only if the reporting person remains employed through the vesting dates; it does not represent immediate liquidity. The later filing date may be noteworthy because insiders generally must report Form 4 transactions within two business days.
Insider Transaction Report
- Award
Stock Option
[F1]2026-04-24+300,000→ 300,000 totalExercise: $8.80Exp: 2036-04-24→ Common Stock (300,000 underlying)
Footnotes (1)
- [F1]The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date.